Genscript Biotech (HKSE:01548) Cash-to-Debt : 4.62 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Genscript Biotech's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.62.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Genscript Biotech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Genscript Biotech's Cash-to-Debt or its related term are showing as below:

HKSE:01548' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.18 Med: 35.72 Max: No Debt
Current: 4.62

During the past 10 years, Genscript Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 4.18. And the median was 35.72.

HKSE:01548's Cash-to-Debt is ranked worse than
56.27% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs HKSE:01548: 4.62

Genscript Biotech Cash-to-Debt Historical Data

The historical data trend for Genscript Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Genscript Biotech Cash-to-Debt Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

17.67

14.02

8.97

4.18

4.62

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial														8.97	5.48	4.18	5.62	4.62

Competitive Comparison of Genscript Biotech's Cash-to-Debt

For the Biotechnology subindustry, Genscript Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Cash-to-Debt falls into.

Genscript Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Genscript Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15057.685	/	(514.494	+	2742.114)
	=	4.62

Genscript Biotech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15057.685	/	(514.494	+	2742.114)
	=	4.62

Genscript Biotech (HKSE:01548) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Genscript Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (HKSE:01548) Headlines

No Headlines